Microvascular dysfunction in malignant hypertension; evaluation of the endothelial glycocalyx.

Microvascular dysfunction in malignant hypertension; evaluation of the endothelial glycocalyx. - Mistletoe

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32232

Enrollment

Registered

2008-08-18

Start date

2008-08-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertensive crisis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 99 years Blood pressure above 120 mmHg diastolic on repeated examination Admission for parenteral bloodpressure lowering treatment with labetalol

Exclusion criteria

Exclusion criteria: Current pregnancy Intoxications (e.g. cocaine, XTC) Hypertensive crises treated with other oral or parenteral drugs than labetalol Contra-indication for beta or alpha blockers.

Design outcomes

Primary

Measure	Time frame
Microvascular glycocalyx volume changes	—

Secondary

Measure	Time frame
Coagulation activation Endothelial activation Glycocalyx degradation products Oxidative stress measurements	—

Countries

Netherlands

Outcome results